Combo Dual Therapy Stent

OrbusNeich
+ 31.33.254.4294
www.orbusneich.com

KEY FEATURES

- Luminal endothelial progenitor-cell–capture coating
- Abluminal sirolimus drug elution
- Biodegradable polymer
- Unique dual-helix design
- Conformable and easily adaptable to side branches

OrbusNeich (Hoevelaken, The Netherlands) announced the CE Mark approval and launch of the Combo dual therapy stent. The Combo stent promotes accelerated vessel healing with an antibody surface coating that captures endothelial progenitor cells circulating in the blood to the device to form a functional endothelial layer. By delivering abluminal sirolimus drug elution from a biodegradable polymer that achieves full and complete dissipation by 90 days, the device maintains the restenotic efficacy of drug-eluting stents while controlling neointimal proliferation and protecting against in-stent thrombosis.

Data from the REMEDEE Study showed the Combo dual therapy stent to be safe and effective, with an overall low rate of clinical events, a low rate of binary restenosis, and no stent thrombosis observed up to 12 months.[1]

"The Combo stent is a fascinating new product that has the potential to preserve the safety benefit from a shortened course of dual antiplatelet therapy while reducing neointimal proliferation powerfully enough for it to be used in patients at high risk of restenosis," said Tim Kinnaird, MD, of the University Hospital of Wales. The device is currently not available in the United States or Japan, the company advised. ■

1. Haude M, Lee SWL, Worthely SG, et al. The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent. J Am Coll Cardiol Interv. 2013;6:334-343.